MyeloMATCH MSRP (Acute Myeloid Leukemia & Myelodysplastic Syndrome) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if blood and bone marrow samples can be tested in a timely manner that allows for the detection of certain markers that could guide cancer treatment.
What is the Condition Being Studied?
Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Who Can Participate in the Study?
Adults ages 18+ who:
- Are suspected to have previously untreated AML or MDS (paarticipants with AML cannot have a history of previously treated myeloproliferative neoplasms)
- Have not received prior anti-cancer therapy for AML or MDS (previous erythroid stimulating agent is not considered prior therapy for the purposes of eligibility)
For more information about this study, please contact the study team at marty.c.cauley@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will have blood draws and bone marrow samples taken for testing.
Study Details
Full Title
MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials
Principal Investigator
Hematologic Oncologist
Protocol Number
IRB:
PRO00116097
NCT:
NCT05564390
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment